

Bod Achieves World First in Phase I Clinical Trial for Sublingual Cannabis Wafer

- **Bod has now successfully dosed its ECs315 cannabis extract in a sublingual wafer – showing that CBD can be delivered into a patients bloodstream using the patented wafer system**
- **First time globally that pharmacokinetics (PK) of a full plant cannabis extract have been evaluated in a Clinical Trial - Pharmacokinetics is the interaction of a drug and its absorption, distribution, metabolism and excretion**
- **Study provides ‘proof of concept’ for Bod’s unique, cannabis sublingual wafer delivery system**
- **Trial now progressing to assess absorption rate of the wafer compared to other delivery methods and products**
- **Bod exploring additional applications for the unique and patented wafer for delivery of other pharmaceutical and OTC products**
- **Clinical Trial on track to conclude this quarter with global and domestic licensing and distribution agreements to follow**

Sydney, Australia – 16 October 2018: Developer and distributor of natural, evidence-based cosmetics and health products including medicinal cannabis, Bod Australia Limited (“Bod”, the “Company”) (ASX: BDA), confirms a major milestone in the Phase I Clinical trial of its proprietary CBD extract ECs315, suspended in a sublingual wafer delivery method (refer image 1).

Bod developed the wafer by utilising products and technology from exclusive partners, Swiss Botanicals extracts manufacturer, Linnea SA and late stage, Singaporean pharmaceutical company, iX Biopharma.

This is the first time on a global scale that the pharmacokinetics (PK) of a full plant cannabis extract have been evaluated under ‘blinded’ clinical trial conditions. Blinded refers to the patient and clinician not knowing if they are using an active drug or placebo and PK refers to how, in this instance ECs315, is absorbed, distributed, metabolised and excreted in the human body.

The next stage of the Clinical Trial entails Bod testing the absorption rate of its patented sublingual wafer, when compared to the ECs315 cannabis extract in currently available oil form. The wafer will also be tested against a competitor's product currently available on the Australian market.

All phases of the Clinical Trial, which commenced in July 2018, will be completed by year end. Following successful completion of the trial, Bod will be well placed on an international scale with access to a unique finished product, containing a standardised and reproducible extract, as well as a patented delivery method.

The Company is actively assessing numerous commercial product opportunities for the distribution, manufacture and licencing of its finished product. Bod will leverage its established channels to market and existing relationships with international counterparties to ensure uptake of its sublingual cannabis wafer.

Bod Australia CEO Jo Patterson said: “The results of this Clinical Trial are outstanding for Bod. It is a major leap forward in developing a proprietary sublingual wafer that could have broad commercial appeal.

“Following success with the Clinical Trial, Bod will retain the rights to a unique, easily reproducible finished product with worldwide patent protection, underpinned by a global brand we are developing. We are also broadening our use

of the proprietary 'WaferiX' technology and pursuing additional research initiatives which test the ECs315 extract on specific conditions such as post chemotherapy nausea and vomiting.

"Bod has multiple commercial, clinical and corporate developments pending and we expect a steady stream of updates in the coming weeks and months"



Image one: Bod Australia's sublingual cannabis wafer in blister packaging

- ENDS -

About Bod Australia:

Bod Australia Limited (ASX:BDA) is a developer, distributor and marketer of health products and supplements, with a focus on plant-based extracts including medicinal cannabis.

Bod is rapidly building an integrated cannabis business, underpinned by agreements with international counterparties Linnea SA, a leading Swiss botanicals extracts manufacturer and iX Biopharma Limited, a late stage Singapore-listed pharmaceutical company. Bod is actively developing a range of over-the-counter and therapeutic products based on its unique, standardised and reproducible Good Manufacturing Practice certified cannabis extracts.

The Company has a large distribution footprint in Australia, selling therapeutics and OTC products to over 1,000 retail outlets, including pharmacies, department stores and healthcare chains. The Company also has distribution agreements with two of Australia's largest pharmacy wholesalers providing it with access to over two thirds of the market.

For more information: bodaustralia.com

For more information please contact:

Jo Patterson
Bod Australia
+61 2 9199 5018

Henry Jordan – Six Degrees Investor Relations
Henry.jordan@sdir.com.au
+61 431 271 538